XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT. | May 9, 2023
BURNABY, British Columbia, Feb. 14, 2022 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a. | February 14, 2022